Investigational drugs for the treatment of allergic rhinitis

Bibliography

• Settipane RA. Demographics and epidemiology of allergic and nonallergic rhinitis. Allergy Asthma Proc 2001;22(4):185-9
   PubMed Web of Science ®Google Scholar
• Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol 2010;126(4):778-83
   PubMed Web of Science ®Google Scholar
• Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999;82(3):233-48
   PubMed Web of Science ®Google Scholar
• Romano-Zelekha O, Graif Y, Garty BZ, et al. Trends in the prevalence of asthma symptoms and allergic diseases in Israeli adolescents: results from a national survey 2003 and comparison with 1997. J Asthma 2007;44(5):365-9
   PubMed Web of Science ®Google Scholar
• Zar HJ, Ehrlich RI, Workman L, et al. The changing prevalence of asthma, allergic rhinitis, and atopic eczema in African adolescents from 1995 to 2002. Pediatr Allergy Immunol 2007;18(7):560-5
   PubMed Web of Science ®Google Scholar
• Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008;122(Suppl 2):S1-84
   PubMed Web of Science ®Google Scholar
• Scadding GK. Recent advances in the treatment of rhinitis and rhinosinusitis. Int J Pediatr Otorhinolaryngol 2003;67(Suppl 1):S201-4
   PubMedGoogle Scholar
• Georgalas C. The role of the nose in snoring and obstructive sleep apnea: an update. Eur Arch Otorhinolaryngol 2011;268(9):1365-73
   PubMed Web of Science ®Google Scholar
• Koinus-Mitchell D, Craig T, Esteban CA, et al. Sleep and allergic disease: a summary of the literature and future directions for research. J Allergy Clin Immunol 2012;130(6):1275-81
   PubMed Web of Science ®Google Scholar
• Vuurman EF, van Veggel LM, Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993;71(2):121-6
   PubMedGoogle Scholar
• Walker S, Khan-Wasti S, Fletcher M, et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007;120(2):381-7
   PubMed Web of Science ®Google Scholar
• Cuffel B, Wamboldt M, Borish L, et al. Economic consequences of comorbid depression, anxiety, and allergic rhinitis. Psychosomatics 1999;40(6):491-6
   PubMed Web of Science ®Google Scholar
• Benninger MS, Benninger RM. The impact of allergic rhinitis on sexual activity, sleep, and fatigue. Allergy Asthma Proc 2009;30(4):358-65
   PubMed Web of Science ®Google Scholar
• D'Alonzo GE Jr. Scope and impact of allergic rhinitis. J Am Osteopath Assoc 2002;102(6 Suppl 2):S2-6
   PubMedGoogle Scholar
• Schatz M, Zeiger RS, Chen W, et al. The burden of rhinitis in a managed care organization. Ann Allergy Asthma Immunol 2008;101(3):240-7
   PubMed Web of Science ®Google Scholar
• Bhattacharyya N. Incremental healthcare utilization and expenditures for allergic rhinitis in the United States. Laryngoscope 2011;121(9):1830-3
   PubMed Web of Science ®Google Scholar
• Torrance GW. Preferences for health outcomes and cost-utility analysis. Am J Manag Care 1997;(Suppl 3):S8-S20
   Google Scholar
• Ray NF, Baraniuk JN, Thamer M, et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol 1999;103(3 Pt 1):401-7
   PubMed Web of Science ®Google Scholar
• Soni A. Allergic rhinitis: trends in use and expenditures, 2000 to 2005. Statistical Brief #204, Agency for Healthcare Research and Quality; Bethesda, MD; 2008
   Google Scholar
• Ciprandi G, Passalacqua G. Allergy and the nose. Clin Exp Immunol 2008;153(Suppl 1):22-6
   PubMedGoogle Scholar
• Rosenwasser L. New insights into the pathophysiology of allergic rhinitis. Allergy Asthma Proc 2007;28(1):10-15
   PubMed Web of Science ®Google Scholar
• Jones N. Allergic rhinitis: aetiology, predisposing and risk factors. Rhinology 2004;42(2):49-56
   PubMed Web of Science ®Google Scholar
• Pawankar R. Inflammatory mechanism in allergic rhinitis. Curr Opin Allergy Clin Immunol 2007;7(1):1-4
   PubMed Web of Science ®Google Scholar
• Seth D, Secord E, Kamat D. Allergic rhinitis. Clin Pediatr (Phila) 2007;46(5):401-7
   PubMed Web of Science ®Google Scholar
• Hart PH. Regulation of the inflammatory response in asthma by mast cell products. Immunol Cell Biol 2001;79(2):149-53
   PubMed Web of Science ®Google Scholar
• Lehman JM, Blaiss MS. Selecting the optimal oral antihistamine for patients with allergic rhinitis. Drugs 2006;66(18):2309-19
   PubMed Web of Science ®Google Scholar
• Orban NT, Saleh H, Durham SR. Chapter 55. In: Adkinson NF Jr, Bochner BS, Busse WW, et al. editors, Allergic and non-allergic rhinitis. 7th edition. Elsevier Mosby, Philadelphia, PA; 2008
   Google Scholar
• Baraniuk JN. Pathogenesis of allergic rhinitis. J Allergy Clin Immunol 1997;99(2):S763-72
   PubMed Web of Science ®Google Scholar
• Broide DH, Paine MM, Firestein GS. Eosinophils express interleukin 5 and granulocyte macrophage colony stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest 1992;90(4):1414-24
   PubMed Web of Science ®Google Scholar
• Chomarat P, Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev Immunol 1998;17(1-4):1-52
   PubMedGoogle Scholar
• Gani F, Pozzi E, Crivellaro MA, et al. The role of patient training in the management of seasonal rhinitis and asthma: clinical implications. Allergy 2001;56(1):65-8
   PubMed Web of Science ®Google Scholar
• Agostinis F, Forti S, Di Berardino F. Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis. Allergy 2010;65(3):410-11
   PubMed Web of Science ®Google Scholar
• Senti G, von Moos S, Kundig TM. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy 2011;66(6):798-809
   PubMed Web of Science ®Google Scholar
• Custovic A, Wijk RG. The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA(2)LEN). Allergy 2005;60(9):1112-15
   PubMed Web of Science ®Google Scholar
• Church MK. H(1)-antihistamines and inflammation. Clin Exp Allergy 2001;31(9):1341-3
   PubMed Web of Science ®Google Scholar
• Hasala H, Moilanen E, Janka-Junttila M, et al. First generation antihistamines diphenhydramine and chlorpheniramine reverse cytokine-afforded eosinophil survival by enhancing apoptosis. Allergy Asthma Proc 2007;28(1):79-86
   PubMed Web of Science ®Google Scholar
• Gengo FM, Manning C. A review of the effects of antihistamines on mental processes related to automobile driving. J Allergy Clin Immunol 1990;86(6 Pt 2):1034-9
   PubMed Web of Science ®Google Scholar
• Verster JC, Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol 2004;92(3):294-303
   PubMed Web of Science ®Google Scholar
• Deruaz C, Leimgruber A, Berney M, et al. Levocetirizine better protects than desloratadine in a nasal provocation with allergen. J Allergy Clin Immunol 2004;113(4):669-76
   PubMed Web of Science ®Google Scholar
• Simons FE, Prenner BM, Finn A Jr, et al. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2003;111(3):617-22
   PubMed Web of Science ®Google Scholar
• Layton D, Wilton L, Boshier A, et al. Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf 2006;29(10):897-909
   PubMed Web of Science ®Google Scholar
• Gentile DA, Friday GA, Skoner DP. Management of allergic rhinitis: antihistamines and decongestants. Immunol Allergy Clin North Am 2000;20:355-68
   Web of Science ®Google Scholar
• Patel D, Garadi R, Brubaker M, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc 2007;28(5):592-9
   PubMed Web of Science ®Google Scholar
• Yáñez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002;89(5):479-84
   PubMed Web of Science ®Google Scholar
• Van Bavel J, Findlay SR, Hampel FC Jr, et al. Intranasal fluticasone propionate is more effective than terfenadine tablets for seasonal allergic rhinitis. Arch Intern Med 1994;154(23):2699-704
   PubMed Web of Science ®Google Scholar
• Kaszuba SM, Baroody FM, de Tineo M, et al. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med 2001;161(21):2581-7
   PubMed Web of Science ®Google Scholar
• Pulleritis T, Praks L, Ristioja V, et al. Comparison of nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109(6):949-55
   PubMed Web of Science ®Google Scholar
• Borish L. Allergic rhinitis: systemic inflammation and implications for management. J Allergy Clin Immunol 2003;112(6):1021-31
   PubMed Web of Science ®Google Scholar
• Barnes ML, Menzies D, Fardon TC, et al. Combined mediator blockade or topical steroid for treating the unified allergic airway. Allergy 2007;62(1):73-80
   PubMed Web of Science ®Google Scholar
• Welsh PW, Stricker WE, Chu CP, et al. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clinic Proc 1987;62(2):125-34
   PubMed Web of Science ®Google Scholar
• Pitsios C, Papadopoulos D, Kompoti E, et al. Efficacy and safety of mometasone furoate vs nedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006;96(5):673-8
   PubMed Web of Science ®Google Scholar
• Ratner PH, Howland WC III, Arastu R, et al. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol 2003;90(5):536-42
   PubMed Web of Science ®Google Scholar
• Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 2007;67(6):887-901
   PubMed Web of Science ®Google Scholar
• Milgrom H, Biondi R, Georgitis JW, et al. Comparison of ipratropium bromide 0.03% with beclomethasone diproprionate in the treatment of perennial rhinitis in children. Ann Allergy Asthma Immunol 1999;83(2):105-11
   PubMed Web of Science ®Google Scholar
• Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102(4 Pt 1):558-62
   PubMed Web of Science ®Google Scholar
• Creticos PS. Immunotherapy with allergens. JAMA 1992;268(20):2834-9
   PubMed Web of Science ®Google Scholar
• Majori M, Caminati A, Corradi M, et al. T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma. Clin Exp Allergy 2000;30(3):341-7
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Durham SR, Global Allergy and Asthma European Network. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007;119(4):881-91
   PubMed Web of Science ®Google Scholar
• Raphael GD, Berger WE, Prenner BM, et al. Efficacy, safety and optimal dose selection of beclomethasone dipropionate nasal aerosol for seasonal allergic rhinitis in adolescents and adults. Curr Med Res Opin 2013;29(10):1329-40
   PubMed Web of Science ®Google Scholar
• Ahlstrom-Emanuelsson C, Anderson M, Persson C, et al. Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis. Clin Exp Allergy 2004;34(5):731-5
   PubMed Web of Science ®Google Scholar
• Atkinson DA, Uryniak T, Simpson B, et al. A comparison of rofleponide palmitate nasal spray (RPNS) with placebo and mometasone furoate nasal spray (MFNS) in adolescent and adult patients with seasonal (mountain cedar) allergic rhinitis. J Allergy Clin Immunol 2004;113(Suppl 2):S175
   PubMedGoogle Scholar
• Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140(6):805-20
   PubMed Web of Science ®Google Scholar
• Casale TB, Kessler J, Romero FA. Safety of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis. Ann Allergy Asthma Immunol 2006;97(4):454-6
   PubMed Web of Science ®Google Scholar
• Greiff L, Cervin A, Ahlstrom-Emanuelsson C, et al. Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res 2012;13:53
   PubMed Web of Science ®Google Scholar
• Barrett EG, Rudolph K, Matthews M, et al. A novel TLR-8 agonist attenuates nasal symptoms/congestion in both dog and human allergen challenge studies. J Inflamm (Lond) 2013;10(Suppl 1):P14
   PubMedGoogle Scholar
• Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy 2011;41(9):1305-12
   PubMed Web of Science ®Google Scholar
• Creticose PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355(14):1445-55
   PubMed Web of Science ®Google Scholar
• Krug N, Gupta A, Badorrek P, et al. Efficacy of the oral chemoattractant receptor homologous moleculre on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 2014;133(2):414-419.e8
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy 2012;67(12):1572-9
   PubMed Web of Science ®Google Scholar
• Fretz H, Valdenaire A, Pothier J, et al. Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist. J Med Chem 2013;56(12):4899-911
   PubMed Web of Science ®Google Scholar
• Gervais FG, Sawyer N, Stocco R, et al. Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist. Mol Pharmacol 2011;79(1):69-76
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Welham MJ, Kotani K, et al. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 1997;94(9):4330-5
   PubMed Web of Science ®Google Scholar
• Harris SJ, Foster JG, Ward SG. PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies. Curr Opin Investig Drugs 2009;10(11):1151-62
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002;297(5583):1031-4
   PubMed Web of Science ®Google Scholar
• Clayton E, Bardi G, Bell SE, et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 2002;196(6):753-63
   PubMed Web of Science ®Google Scholar
• Ali K, Bilancio A, Thomas M, et al. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 2004;431(7011):1007-11
   PubMed Web of Science ®Google Scholar
• Alenmyr L, Greiff L, Andersson M, et al. Effect of mucosal TRPV1 inhibition in allergic rhinitis. Basic Clin Pharmacol Toxicol 2012;110(3):264-8
   PubMed Web of Science ®Google Scholar
• Bareille P, Murdoch RD, Denyer J, et al. The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis. Int J Clin Pharmacol Ther 2013;51(7):576-84
   PubMed Web of Science ®Google Scholar
• Valenta R, Niederberger R. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007;119(4):826-30
   PubMed Web of Science ®Google Scholar
• Norman PS, Ohman JL, Long AA, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996;154(6 Pt 1):1623-8
   PubMed Web of Science ®Google Scholar
• Larche M. Update on the current status of peptide immunotherapy. J Allergy Clin Immunol 2007;119(4):906-9
   PubMed Web of Science ®Google Scholar
• Focke-Tejkl M, Valenta R. Safety of engineered allergen-specific immunotherapy vaccines. Curr Opin Allergy Clin Immunol 2012;12(5):555-63
   PubMed Web of Science ®Google Scholar
• Zhu D, Kepley CL, Zhang K, et al. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005;11(4):446-9
   PubMed Web of Science ®Google Scholar
• Kalensnikoff J, Galli SJ. Nipping cat allergy with fusion proteins. Nat Med 2005;11(4):381-2
   PubMed Web of Science ®Google Scholar
• Creticos PS, Shroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355(14):1445-55
   PubMed Web of Science ®Google Scholar
• Hessel EM, Chu M, Lizcano JO, et al. Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J Exp Med 2005;202(11):1563-73
   PubMed Web of Science ®Google Scholar
• Frati F, Moingeon P, Marcucci F, et al. Mucosal immunization application to allergic disease: sublingual immunotherapy. Allergy Asthma Proc 2007;28(1):35-9
   PubMed Web of Science ®Google Scholar
• La Rosa M, Ranno C, Andre C, et al. Double-blind placebo-controlled evaluation of sublingual swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999;104(2 Pt 1):425-32
   PubMed Web of Science ®Google Scholar
• Lima MT, Wilson D, Pitkin L, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002;32(4):507-14
   PubMed Web of Science ®Google Scholar
• Smith H, White P, Annila I, et al. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 2004;114(4):831-7
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Cirillo I, Fenoglio D, et al. Sublingual immunotherapy induces spirometric improvement associated with IL-10 production: preliminary reports. Int Immunopharmacol 2006;6(8):1370-3
   PubMed Web of Science ®Google Scholar
• Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003;111(3):437-48
   PubMed Web of Science ®Google Scholar
• Merck Sharp and Dohme Corp. Biologics License Application (BLA) for RAGWITEK™ [Standardized allergen extract, short ragweed (Ambrosia artemisiifolia)] sublingual tablet for oral use. Allergenic Products Advisory Committee (APAC) Meeting. 2014. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/allergenicproductsadvisorycommittee/ucm382841.pdf
   Google Scholar
• Merck Sharp and Dohme Corp. Biologics License Application (BLA) for Timothy Grass Pollen Allergen Extract Tablet for Sublingual use. Allergenic Products Advisory Committee (APAC) Meeting. 2013. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/AllergenicProductsAdvisoryCommittee/UCM378092.pdf
   Google Scholar
• Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011;66(6):740-52
   PubMed Web of Science ®Google Scholar
• Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117(4):802-9
   PubMed Web of Science ®Google Scholar
• Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118(2):434-40
   PubMed Web of Science ®Google Scholar
• Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120(6):1338-45
   PubMed Web of Science ®Google Scholar
• Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123(1):160-6
   PubMed Web of Science ®Google Scholar
• Creticos PS, Maloney J, Bernstein DI, et al. Randomized controlled trial of ragweed allergy immunotherapy tablets in North American and European adults. J Allergy Clin Immunol 2013;131(5):1342-9
   PubMed Web of Science ®Google Scholar
• Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011;127(1):64-71
   PubMed Web of Science ®Google Scholar
• Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012;130(6):1327-34
   PubMed Web of Science ®Google Scholar
• Esch RE, Bush RK, Peden D, Lockey RF. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Ann Allergy Asthma Immunol 2008;100(5):475-81
   PubMed Web of Science ®Google Scholar
• Creticos PS, Balcer-Whaley SL, Moldt P, et al. Comparison of compositional differences and relative potency between different manufacturers of ragweed pollen extracts. J Allergy Clin Immunol 2007;119:abstract S57
   Web of Science ®Google Scholar
• Creticos PS, Balcer-Whaley SL, Moldt P, et al. Safety and efficacy of oral immunotherapy with a microencapsulated ragweed pollen extract (MRPE) in patients with ragweed induced seasonal allergic rhinitis [abstract]. Presented at the 27th Symposium of Collegium Internationale Allergologicum in Curacao; May 2008; Curacao
   Google Scholar
• Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008;105(46):17908-12
   PubMed Web of Science ®Google Scholar
• Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012;129(5):1290-6
   PubMed Web of Science ®Google Scholar
• Hylander T, Latif L, Petersson-Westin U, et al. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol 2013;131(2):412-20
   PubMed Web of Science ®Google Scholar
• Witten M, Malling HJ, Blom L, et al. Is a intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol 2013;132(5):1248-52
   PubMed Web of Science ®Google Scholar
• Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012;129(1):128-35
   PubMed Web of Science ®Google Scholar
• Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009;124(5):997-1002
   PubMed Web of Science ®Google Scholar
• Agosti JM, Sanes-Miller CH. Novel therapeutic approaches for allergic rhinitis. Immunol Allergy Clin North Am 2000;20:401
   Web of Science ®Google Scholar
• Chervinksky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003;91(2):160-7
   PubMed Web of Science ®Google Scholar
• Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004;113(2):297-302
   PubMed Web of Science ®Google Scholar
• Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001;286(23):2956-67
   PubMed Web of Science ®Google Scholar
• Kopp MV, Brauburger J, Riedinger F, et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;110(5):728-35
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy N, Oriss TB, Paglia M, et al. Activation of c-Kit in dendritic cells regulates T helper differentiation and allergic asthma. Nat Med 2008;14(5):565-73
   PubMed Web of Science ®Google Scholar
• Oriss TB, Krishnamoorthy N, Ray P, et al. Dendritic cell c-kit signaling and adaptive immunity: implications for the upper airways. Curr Opin Allergy Clin Immunol 2014;14(1):7-12
   PubMed Web of Science ®Google Scholar
• Radulovic S, Calderon MA, Wilson D, et al. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010;8(12):CD002893
   PubMed Web of Science ®Google Scholar
• Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60(1):4-12
   PubMed Web of Science ®Google Scholar